Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage

Clinical Endocrinology

Volumn 58, Issue 4, 2003, Pages 471-481

  Lucas, Tomás ^a,b   Astorga, Ricardo ^a,c   Catalá, Miguel ^a,d   Albero, ^e   Astorga, ^c   Leal, ^c   Trujillo, ^c   Venegas, ^c   Villamil, ^c   Navarro, ^c   Barberia ^f   Forga, ^f   Iriarte, ^f   Anda, ^f   Calderon ^f   Olier, ^f   Benito, ^g   Corpas, ^g   Galvez ^g   Cano, ^h   Garcia Rico ^h   Goday, ^h   Casal, ⁱ   Casanueva, ^j   Peino ^j   Catala ^d   Tenes ^d   Charro, ^k   Duran ^k   Bordiu, ^k   Diaz Cadorniga ^l   Botas, ^l   Delgado, ^l   De Leiva, ^m   Webb, ^m   Albareda, ^m   Caballero, ^m   De Pablos, ⁿ   Garcia ⁿ   Martinez J ⁿ   Martinez P ⁿ   Ponce, ⁿ   Sanchez Moro ⁿ   Santana, ⁿ   Egas ⁿ   Molero, ⁿ   Del Pozo, ^o   De León, Maestro ^o   Rovira, ^o   Dominguez ^p   Rivera, ^p   Escobar, ^q   Torres, ^q   Penafiel ^q   Esteva, ^r   Gonzalez ^r   De Adana, Ruiz ^r   Faure, ^s   Roche, ^s   Pie, ^s   Freijanes, ^t   Amado, ^t   Montalban ^t   Otero, ^t   Pesquero, ^t   Garcia Mayor ^u   Paramo ^u   Gavilan ^v   Aguilar, ^v   Ortego, ^v   Gil, ^w   Suarez ^w   Aguado, ^w   Valoria, ^w   Halperin, ^x   Vilardell, ^x   Sesmilo, ^x   Hawkins, ^y   Ruiz Valdepenas ^y   Hernandez ^z   Munoz ^z   Gomez Balaguer ^z   Inigo ^z   Morillas, ^z   Pena ^z   Herrera, ^aa   Gonzalo, ^aa   Azriel, ^aa   Jara, ^ab   Carrillo, ^ab   Salmeron ^ab   Lucas, ^ac   Barcelo ^ac   Estrada, ^ac   Garcia Uria ^b   Pineda, Eva ^ad   more..

^a Department of Endocrinology ^*  (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f Instituto de Investigación Sanitaria de Navarra   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL DE CABUEÑES   (Spain)

^j HOSPITAL DE CONXO   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^m HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁿ Hospital Nuestra Senora del Pino   (Spain)

^o HOSPITAL MÚTUA DE TERRASSA   (Spain)

^p HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^q HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^r HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^s HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^t HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^u HOSPITAL XERAL CÍES   (Spain)

^v HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^w Pediatric Surgery Department Complejo Asistencial Universitario de León León   (Spain)

^x Dirección de Enfermeria   (Spain)

^y HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^z HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^aa Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^ab HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^ac HOSPITAL SAN PEDRO   (Spain)

^ad IPSEN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE;

ADULT; ARTICLE; CANCER HORMONE THERAPY; CANCER INVASION; CANCER SURGERY; CAVERNOUS SINUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOPHYSIS ADENOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OPEN STUDY; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SURGICAL APPROACH; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOMA; ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037381257     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.01741.x     Document Type: Article

References (39)

1. Abosch, A., Tyrrell, J.B., Lamborn, K.R., Hannegan, L.T., Applebury, C.B. & & Wilson, C.B. (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism, 83, 3411-3418.
2. Alexander, L., Appleton, D., Hall, R., Ross, W.M. & Wilkinson, R. (1980) Epidemiology of acromegaly in the Newcastle region. Clinical Endocrinology, 12, 71-79.
3. Al-Maskari, M., Gebbie, J. & Kendall-Taylor, P. (1996) The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clinical Endocrinology, 45, 415-421.
4. Barbanoj, M.J., Antonijoan, R., Morte, A., Grinyó, J.M., Solá, R., Vallés, J., Peraire, C., Cordero, J.A., Muñoz, A., Jané, F. & Obach, R. (1999) Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. Clinical Pharmacology and Therapeutics, 66, 485-491.
5. Barkan, A.L. (1989) Acromegaly. Diagnosis and therapy. Endocrinology and Metabolism Clinics of North America, 18, 277-310.
6. Barkan, A.L., Lloyd, R.V., Chandler, W.F., Hatfield, M.K., Gebarski, S.S., Kelch, R.P., Beitins, I.Z. (1988) Preoperative treatmentt of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. Journal of Clinical Endocrinology and Metabolism, 67, 1040-1048.
7. Bengtsson, B.A., Eden, S., Ernest, I., Oden, A. & Sjogren, B. (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica, 223, 327-335.
8. Bowker, A.H. (1948) A test for Symmetry in contingency tables. Journal of American Statistician Association, 43, 572-574.
9. Caron, P., Morange-Ramos, I., Cogne, M. & Jaquet, P. (1997) Three year follow-up of acromegalic patients treated with intramuscular slow release lanreotide. Journal of Clinical Endocrinology and Metabolism, 82, 18-22.
10. Chiodini, P.G., Cozzi, R., Dallabonzana, D., Oppizzi, G., Verde, G., Petroncini, M., Liuzzi, A.L., del Pozo, E. (1987) Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. Journal of Clinical Endocrinology and Metabolism, 64, 447-453.
11. Colao, A., Ferone, D., Cappabianca, P., Basso de Caro, M.L., Marzullo, P. & Monticelli, A. (1997) Alfieri, A., Merola, B., Cali, A., Divitiis, E. & Lombardi, G. Effect of octreotide pretreatment on surgical outcome in acromegaly. Journal of Clinical Endocrinology and Metabolism, 82, 3308-3314.
12. Colao, A., Ferone, D., Marzullo, P., Cappabianca, P., Cirillo, S., Boerlin, V., Lancranjan, I. & Lombardi, G. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism, 86, 2779-2786.
13. Di Chiro, G. & Nelson, K. (1962) The volume of the sella turcica. American Journal of Roentgenology, 87, 989-1008.
14. Ducasse, M.C.R., Tauber, J.P., Tourre, A., Bonafe, A., Babin, T.H., Tauber, M.T., Harris, A.G. (1987) Bayard, F. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995. Journal of Clinical Endocrinology and Metabolism, 65, 1042-1046.
15. Etxabe, J., Gaztambide, S., Latorre, P. & Vazquez, J.A. (1993) Acromegaly: an epidemiological study. Journal of Endocrinological Investigation, 16, 181-187.
16. Ezzat, S., Snyder, P.J., Young, W.F., Boyajy, L.D. Newman, C., Klibanski, A., Molitch, M.E., Boyd, A.E., Sheeler, L., Cook, D.M., Malarkey, W.B., Jackson, I., Vance L., Thorner, M.O., Barkan, A., Frohman, L.A. & Melmed S. (1992) Octreotide treatment of acromegaly: a randomized, multicenter study. Annals of Internal Medicine, 117, 711-718.
17. Ezzat, S., Horvath, E., Harris, A.G. & Kovacs, K. (1994) Morphological effects of octreotide on growth hormone-producing pituitary adenomas. Journal of Clinical Endocrinology and Metabolism, 79, 113-118.
18. Frohman, L.A. (1996) Acromegaly: what constitutes optimal therapy. Journal of Clinical Endocrinology and Metabolism, 81, 443-445.
19. Hardy, J. (1971) Transsphenoidal hypophysectomy. Journal of Neurosurgery, 34, 582-594.
20. Hofland, L.J., van Koeetsveld, P.M., van Vroonhoven, C.C., Stefanko, S.Z. & Lamberts, S.W. (1989) Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone. Journal of Clinical Endocrinology and Metabolism, 68, 613-620.
21. Krishna, A.Y. & Phillips, L.S. (1994) Management of acromegaly: a review. The American Journal of the Medical Sciences, 308, 370-375.
22. Lamberts, S.W., Uitterlinden, P., Verschoor, L., van Dongen, K.J. & del Pozo, E. (1985) Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. New England Journal of Medicine, 313, 1576-1580.
23. Lamberts, S.W., Uitterlinden, P. & del Pozo, E. (1987) SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. Journal of Clinical Endocrinology and Metabolism, 65, 703-710.
24. Lamberts, S.W., Van Der Lely, A.J., de Herder, W.W. & Hofland, L.J. (1996) Octreotide. New England Journal of Medicine, 334, 246-254.
25. Lucas-Morante, T., García-Uría, J., Estrada, J., Saucedo, G., Cabello, A., Alcañiz, J., & Barceló, B (1994) Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. Journal of Neurosurgery, 81, 10-14.
26. Lundin, P. & Pedersen, F. (1992) Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer-Assisted Tomography, 16, 519-528.
27. Lundin, P., Edén Engström, B., Karlsson, F.A. & Burman, P. (1997) Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. American Journal of Neuroradiology, 18, 765-772.
28. Melmed, S., Dowling, R.H., Frhoman, L., Ho, K., Lambers, S.W., LaMont, J.T., Sassolas, G., Schoenfield, L., Snyder, P.J. & Wass, J.A. (1994) Consensus statement: benefits versus risks of medical therapy for acromegaly. American Journal of Medicine, 97, 468-473.
29. Plöckinger, U., Reichel, M., Fett, U., Saeger, W. & Quabbe, H.J. (1994) Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas. effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. Journal of Clinical Endocrinology and Metabolism, 79, 1416-1423.
30. Puchner, M.J., Knappe, U.J. & Lüdecke, D.K. (1995) Pituitary surgery in elderly patients with acromegaly. Neurosurgery, 36, 677-683.
31. Randall, R.V. (1989) Acromegaly and gigantism. In. Endocrinology (ed. L. J. De Groot), pp. 330-350. W.B. Saunders, Philadelphia.
32. Sachs, L. (1982) Rank analysis of variance for several correlated samples. In: Applied Statistics A Handbook of Techniques, pp. 549-558. Springer-Verlag, New York.
33. Sheaves, R., Jenkins, P., Blackburn, P., Huneldl, A.H., Afshar, F., Medbak, S., Grossman, A.B., Besser, G.M. & Wass, J.A. (1996) Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clinical Endocrinology, 45, 407-413.
34. Spinas, G.A., Zapf, J., Landolt, A.M., Stuckmann, G. & Froesch, E.R. (1987) Pre-operative treatment of five acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinologica, 114, 249-256.
35. Stevenaert, A. & Beckers, A. (1993) Presurgical octreotide treatment in acromegaly. Acta Endocrinologica, 129 (Suppl 1), 18-20.
36. Swearingen, B., Barker, F.G., Katznelson, L., Biller, B.M., Grinspoon, S., Klibanski, A., Moayery, N., Black, P.M., Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419-3426.
37. Tolis, G., Yotis, A., del Pozo, E. & Pitoulis, S. (1986) Therapeutic efficacy of a somatostatin analogue (SMS 201-995) in active acromegaly. Journal of Neurosurgery, 65, 37-40.
38. Wright, A.D., Hill, D.M., Lowy, C. & Fraser, T.R. (1970) Mortality in acromegaly. Quarterly Journal of Medicine, 39, 1-16.
39. Zgliczynski, W., Zgliczynski, S., Jeske, W., Bonicki, W., Podgórski, J. & Królicki, L. (1997) The somatostatin analog (SR-lanreotide) pretreatment improves surgical outcome in acromegalic patients harbouring pituitary tumors with somatostatin receptors. Journal of Endocrininological Investigations, 20 (Suppl. 7), 45-47.